Cite
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer.
MLA
Lee, Mi-Sook, et al. “IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer.” Molecular Therapy Oncolytics, vol. 16, Jan. 2020, pp. 188–96. EBSCOhost, https://doi.org/10.1016/j.omto.2019.12.009.
APA
Lee, M.-S., Jung, K., Song, J.-Y., Sung, M.-J., Ahn, S.-B., Lee, B., Oh, D.-Y., & Choi, Y.-L. (2020). IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer. Molecular Therapy Oncolytics, 16, 188–196. https://doi.org/10.1016/j.omto.2019.12.009
Chicago
Lee, Mi-Sook, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, and Yoon-La Choi. 2020. “IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer.” Molecular Therapy Oncolytics 16 (January): 188–96. doi:10.1016/j.omto.2019.12.009.